MedTrace Logo

Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas

NCT02978677 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-08-03

No results posted yet for this study

Summary

The trial evaluates the effect of a moderately increased radiation dose in patients with atypical (grade II) and anaplastic (grade III) meningioma after incomplete or no surgery. Endpoint is recurrence-free survival after 5 years.

Conditions

  • Meningioma

Interventions

RADIATION

Radiotherapy 68 Gy(RBE)

Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton

RADIATION

Radiotherapy 72 Gy(RBE)

Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton

RADIATION

Radiotherapy 60 Gy(RBE)

Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton

Sponsors & Collaborators

  • German Cancer Research Center

    collaborator OTHER

  • Radiation Oncology Working Group of the German Cancer Society

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Mechthild Krause, Prof. · Technische Universität Dresden, German Cancer Consortium, Helmholtz-Zentrum Dresden - Rossendorf

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2028-12-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978677 on ClinicalTrials.gov